A short podcast clip with Terry Dubrow talks up retatrutide's commercial potential. Little detail beyond the bold money claim.
Recap by typeshit. Post by Facebook on Facebook.
The surgeon says that after a 45 lb loss on a GLP-1, getting enough daily protein with a low appetite becomes the harder part.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
The writer cites a Gallup survey putting about 11 percent of Americans on GLP-1s and argues the real share is likely higher, and wants use discussed openly.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
She points out the only categorical A1C figure reported: 73.5% on CagriSema hit 6.5% or lower from a baseline of 8.0, versus 15.9% on placebo.
@JCanNuSH says Lilly held an investor call for EASD 2026 with no archived audio, and posts a slide with added Phase 3 details on EloraTZP.
Loading…